Study of LX4211 in Subjects With Type 2 Diabetes Mellitus
Study of LX4211 in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety, tolerability, and efficacy of LX4211
 versus a placebo control in subjects with type 2 diabetes mellitus.
Inclusion Criteria:

 -  Males and females (non-childbearing potential), aged 18-65 years

 -  Diagnosis of Type 2 diabetes mellitus for at least 6 months prior to screening

 -  Fasting plasma glucose ≤ 240 mg/dL prior to metformin washout

 -  Body mass index < 42 kg/m^2

 -  HbA1c value of 7 to 11%

 -  C-peptide ≥ 1.0 ng/mL

 -  Ability to provide written informed consent

 Exclusion Criteria:

 -  History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic
 syndrome, incontinence, or nocturia

 -  Use of any blood glucose lowering agent other than metformin

 -  Prior exposure to insulin, thiazide, or loop diuretics within 4 weeks prior to
 screening

 -  Laboratory or electrocardiogram abnormalities deemed significant by the Sponsor or the
 Investigator

 -  Positive test result for glutamic acid decarboxylase (GAD) antibody

 -  Surgery within 6 months of screening

 -  Exposure to any investigational agent or participation in any investigational trial
 within 30 days prior to Day 1

 -  Hypersensitivity to an SGLT2 inhibitor

 -  History of drug or alcohol abuse within the last 12 months